title: Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
abstract: OBJECTIVE
  Accurate staging of mediastinal lymph nodes metastases is critical for determining the application of stereotactic body radiation therapy (SBRT) for patients with early stage non-small cell lung cancer (NSCLC). In this multicenter study the accuracy of (18)F-FDG PET/CT to detect lymph node metastases was evaluated for early stage NSCLC.
  
  
  METHODS
  The data from the patients with stage1 NSCLC who received preoperative (18)F-FDG PET/CT staging and radical surgery was retrospectively reviewed of five centers from February 2004 to August 2010. The lymph node metastases were confirmed histopathologically after radical surgery. And the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were calculated for PET/CT staging.
  
  
  RESULTS
  Two hundred patients were enrolled. The sensitivity, specificity, accuracy, PPV and NPV for lymph node metastases on PET/CT were 44%, 83%, 78%, 29% and 91%, respectively. There were eight and 19 cases positive for lymph node metastases with central (n=62) and peripheral (n=138) NSCLC (P>0.05), respectively.
  
  
  CONCLUSIONS
  (18)F-FDG PET/CT was specific in N(0) staging for T(1-2) NSCLC. The NPV was about 91% in clinical N(0) patients, suggested that (18)F-FDG PET/CT may help to accurately stage N(0) patients and thus identify patients for SBRT.
authors.affiliation: Department of Radiation Oncology, Key Laboratory of Radiation Oncology of Shandong Province, Jinan, China. daisylinjinan@163.com
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Li
authors.forename: Huaqi
authors.initials: H
authors.lastname: Zhang
authors.forename: Ligang
authors.initials: L
authors.lastname: Xing
authors.forename: Honglian
authors.initials: H
authors.lastname: Ma
authors.forename: Peng
authors.initials: P
authors.lastname: Xie
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.forename: Xiangying
authors.initials: X
authors.lastname: Xu
authors.forename: Jinbo
authors.initials: J
authors.lastname: Yue
authors.forename: Xindong
authors.initials: X
authors.lastname: Sun
authors.forename: Xudong
authors.initials: X
authors.lastname: Hu
authors.forename: Ming
authors.initials: M
authors.lastname: Chen
authors.forename: Wengui
authors.initials: W
authors.lastname: Xu
authors.forename: Lusheng
authors.initials: L
authors.lastname: Chen
authors.forename: Jinming
authors.initials: J
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18